金河生物(002688) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was ¥2,122,705,317.42, representing a 2.15% increase compared to ¥2,077,988,730.16 in 2021[6]. - The net profit attributable to shareholders decreased by 19.63% to ¥75,543,369.47 in 2022 from ¥93,992,380.84 in 2021[6]. - The basic earnings per share fell by 28.35% to ¥0.0968 in 2022, down from ¥0.1351 in 2021[6]. - The total assets increased by 10.85% to ¥4,505,582,532.92 at the end of 2022, compared to ¥4,064,525,859.70 at the end of 2021[6]. - The company's cash flow from operating activities decreased by 18.63% to ¥124,471,194.04 in 2022 from ¥152,978,505.57 in 2021[6]. - The weighted average return on equity decreased by 1.72 percentage points to 3.09% in 2022 from 4.81% in 2021[6]. - The company reported a net profit of -¥26,914,451.49 in Q4 2022, contrasting with profits in the first three quarters[23]. - The company reported a net profit attributable to shareholders of 75.54 million yuan, a decrease of 19.63% compared to the previous year[40]. - The overall revenue for the reporting period increased by CNY 16.83 million, a growth of 2.34% compared to the same period last year[49]. - The net profit for the reporting period decreased by CNY 8.53 million, a decline of 33.60% year-on-year[49]. Revenue Breakdown - Revenue from veterinary chemical drugs was 983.93 million yuan, a decrease of 7.71%, accounting for 46.35% of total revenue[40]. - Revenue from veterinary biological products increased by 13.19% to 330.17 million yuan, making up 15.55% of total revenue[40]. - The environmental business saw a revenue increase of 25.07%, reaching 107.58 million yuan, which accounted for 5.07% of total revenue[40]. - The revenue from the agricultural processing industry increased by CNY 55.02 million, a growth of 10.76% year-on-year[55]. - Domestic sales accounted for 65.61% of total revenue, increasing by 7.84% compared to the previous year[56]. - Direct sales revenue reached CNY 1,578,151,290, a year-on-year increase of 29.06%[57]. - The revenue from Pharmgate Inc. increased by CNY 88.06 million, a growth of 22.88% compared to the previous year[52]. - The revenue from the environmental business increased by CNY 28.04 million, representing an 18.51% growth compared to the previous year[51]. Cost and Expenses - The company's operating costs reached 1,508.91 million CNY, a year-on-year increase of 5.75%, with veterinary chemical drugs accounting for 46.90% of total operating costs[43]. - The gross profit margin decreased by 2.42 percentage points compared to the previous year due to the increase in operating costs outpacing revenue growth[43]. - The total cost of raw materials for veterinary chemical drugs was approximately 400.69 million, accounting for 56.61% of the total operating costs, showing a slight decrease of 0.18% compared to 2021[63]. - The total sales expenses increased by 6.70% to approximately 130.72 million in 2022, compared to 122.51 million in 2021[68]. - Research and development expenses rose by 13.89% to approximately 82.28 million in 2022, compared to 72.25 million in 2021, reflecting increased investment in vaccine projects and new product development[68]. Market and Competition - The veterinary medicine industry is experiencing increased concentration, with the top 31 companies accounting for 80.4% of total sales in the biological products sector[29]. - The company is facing intensified competition and opportunities in the veterinary medicine market due to regulatory changes and increased foreign investment[30]. - The company is actively expanding into the pet medicine sector, with plans to increase product variety and scope in the future[33]. - The company is focusing on strategic adjustments in product structure to enhance product value and expand business scale[46]. Research and Development - The company has a strong emphasis on research and development, with four major technology platforms for vaccine production and significant advancements in product upgrades[37]. - R&D investment increased by 39.78% to ¥122,010,847.05 in 2022, representing 5.75% of operating revenue[71]. - The number of R&D personnel rose to 252, a 4.13% increase from 2021, with a notable increase in PhD holders by 20%[71]. - The company is focusing on new product development in veterinary vaccines, with several new products expected to be launched in the coming years[33]. Corporate Governance - The company maintains independent operations and governance, with no interference from controlling shareholders in decision-making processes[126]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[126]. - The company has established a robust financial management system, including independent accounting and tax reporting[130]. - The company complies with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[127]. Environmental Responsibility - The company adheres to various environmental standards, including GB13271-2014J for boiler emissions and GB37823-2019 for pharmaceutical industry emissions[172]. - The company has implemented real-time monitoring of emissions for various pollutants, ensuring adherence to environmental standards[176]. - The company has established a zero discharge wastewater project, ensuring that treated water meets the required pollution discharge standards[176]. - In 2022, the company invested CNY 1.353 million in environmental governance facilities and paid CNY 0.6981 million in environmental protection tax[178]. Future Outlook - The company plans to continue focusing on product development and market expansion to mitigate the impact of market fluctuations[58]. - The company aims to become a technology-driven, leading animal health company within the next 5-10 years[115]. - The company anticipates a revenue growth target of 20% for the next fiscal year, driven by new product launches and market penetration strategies[89]. - The company plans to enhance its supply chain efficiency, targeting a 15% reduction in operational costs by 2024[137].